The effect of sertraline on methadone plasma levels in methadone- maintenance patients

American Journal on Addictions

Volumn 9, Issue 1, 2000, Pages 63-69

  Hamilton, Steven P ^a   Nunes, Edward V ^b   Janal, Malvin ^b   Weber, Laurie ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; PLACEBO; SERTRALINE;

ANXIETY NEUROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; HUMAN; METHADONE TREATMENT; OPIATE ADDICTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034058726     PISSN: 10550496     EISSN: None     Source Type: Journal    
DOI: 10.1080/10550490050172236     Document Type: Article

References (33)

1. Rounsaville BJ, Weissman MM, Crits-Christoph K, et al. Diagnosis and symptoms of depression in opiate addicts: course and relationship to treatment outcome. Arch Gen Psychiatry. 1982;39: 151-156.
2. Nunes EV, Quitkin FM, Donovan SJ, et al. Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. Arch Gen Psychiatry. 1998;55:153-160.
3. Titievsky J, Seco G, Barranco M, et al. Doxepin as adjunctive therapy for depressed methadone maintenance patients: a double-blind study. J Clin Psychiatry. 1982;43:454-456.
4. Woody GE, O'Brien CP, Rickels K. Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin in combination with methadone. Am J Psychiatry. 1975;132:447-450.
5. Kaul B, Davidow B. Drug abuse patterns of patients on methadone treatment in New York City. Am J Drug Alcohol Abuse. 1981;8:17-25.
6. Kosten TR, Gawin FH, Morgan C, et al. Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse. Am J Drug Alcohol Abuse. 1990;16:329-336.
7. Maany I, Dhopesh V, Arndt IO, et al. Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatry. 1989;146:1611-1613.
8. Hamilton SP, Klimchak C, Nunes EV. Treatment of depressed methadone maintenance patients with nefazodone: a case series. Am J Addict. 1998;7: 309-312.
9. Petrakis I, Carroll KM, Nich C, et al. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug Alcohol Depend. 1998;50:221-226.
10. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153:311-320.
11. Wu D, Otton SV, Sproule BA, et al. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol. 1993;35:30-34.
12. Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996;9:365-373.
13. Eap CB, Bertschy G, Powell K, et al. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol. 1997;17:113-117.
14. Liu S-J, Wang RIH. Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome. Am J Psychiatry. 1984;141:1287-1288.
15. Tong TG, Benowitz NL, Kreek MJ. Methadone-disulfiram interaction during methadone maintenance. J Clin Pharmacol. 1980;20:506-513.
16. Tong TG, Pond SM, Kreek MJ, et al. Phenytoininduced methadone withdrawal. Ann Int Med. 1981;94:349-351.
17. Bertschy G, Baumann P, Eap CB, et al. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit. 1994;16:42-45.
18. Bertschy G, Eap CB, Powell K, et al. Fluoxetine addition to methadone in addicts: pharmacokinetic aspects. Ther Drug Monit. 1996;18:570-572.
19. Nunes EV, Goehl L, Seracini A, et al. Evaluation of depression and panic disorder in methadone patients using a modification of the Structured Clinical Interview for DSM-III-R: test-retest reliability. Am J Addict. 1996;5:241-248.
20. Sullivan HR, Marshall FJ, McMahon RE. Mass fragmentographic determination of unlabeled and deuterium labeled methadone in human plasma. Possibilities for measurement of steady state pharmacokinetics. Mass Spectrom. 1975;2:197-200.
21. Wolff K, Sanderson M, Hay AWM, et al. Methadone concentrations in plasma and their relationship to drug dosage. Clin Chem. 1991;37:203-209.
22. Holmstrand J, Änggȧrd E, Gunne L-M. Methadone maintenance: plasma levels and therapeutic outcome. Clin Pharmacol Ther. 1978;23:175-180.
23. Iribarne C, Dreano Y, Bardou LG, et al. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology. 1997;117: 13-23.
24. Joblin M, Ghose K. Possible interaction of sertraline with carbamazepine. NZ Med J. 1994;107.
25. Chitasombat P, Willenbring ML, Maddux T, et al. Reliability of methadone plasma levels in methadone maintenance. Am J Addict. 1995;4:351-355.
26. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 1992;34: 265.
27. von Moltke LL, Greenblatt DJ, Duan SX, et al. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacology. 1996;128:398-407.
28. Huang J, Guo WC, Lai MD, et al. Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Drug Metab Dispos. 1999;27: 98-101.
29. Nilsson M-I, Änggȧrd E, Holmstrand J, et al. Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase. Eur J Clin Pharmacol. 1982;22:343-349.
30. Torrens M, Castillo C, San L, et al. Plasma methadone concentrations as an indicator of opiod withdrawal symptoms and heroin use in a methadone maintenance program. Drug Alcohol Depend. 1998;193:193-200.
31. Brockmeyer NH, Merlins L, Goos M. Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. Klin Wochenschr. 1991;69:16-18.
32. Iribarne C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N-dealkylation by three HIV-1 protease inhibitors. Drug Metab Dispos. 1998;26:257-260.
33. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1997;32:1-21.